Search

Your search keyword '"Fehr, M."' showing total 169 results

Search Constraints

Start Over You searched for: Author "Fehr, M." Remove constraint Author: "Fehr, M." Database Unpaywall Remove constraint Database: Unpaywall
169 results on '"Fehr, M."'

Search Results

1. P268 Impact of the 2020 COVID-19 lockdown in Switzerland on physical activity in patients with early breast cancer under aromatase-inhibitor therapy. A subanalysis of the SAKK 95/17 WISE trial

3. Effect of a 24 week home-based walking program on the incidence of aromatase inhibitor induced musculoskeletal pain: The WISE prospective, randomized, multicenter trial [SAKK 95/17]

4. Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome

6. PROGNOSTIC FACTORS IN ELDERLY PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA ‐ A JOINT ANALYSIS OF TWO CLINICAL DATABASES

7. SAKK 36/13 ‐ IBRUTINIB PLUS BORTEZOMIB AND IBRUTINIB MAINTENANCE FOR RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: FINAL REPORT OF A PHASE I/II TRIAL OF THE EUROPEAN MCL NETWORK

8. Retrospective multicenter analysis comparing conventional with oncoplastic breast conservation: oncologic and surgical outcome in women with high risk breast cancer from the OPBC-01/iTOP2 study

10. Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland

11. 345P Optimal dose of eribulin as first line treatment in elderly patients ≥ 70 years with advanced breast cancer: A multicenter phase II trial [SAKK 25/14]

12. Experimentelle Unfallchirurgie III Preisträgersitzung

16. Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers

17. CLINICAL CHARACTERISTICS AND OUTCOME OF PATIENTS WITH HODGKIN'S LYMPHOMA OLDER THAN 60 YEARS TREATED IN SWITZERLAND OVER THE LAST 17 YEARS

20. Onkologie

21. Endoskopie/ Gynäkologie

22. Fertilität / Geburtshilfe

23. Incidence of hypocalcemia in a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12 (REDUSE)

25. Impact of a surgical sealing patch on lymphatic drainage after axillary dissection for breast cancer. Multicenter randomized phase III SAKK 23/13 trial

27. High thromboembolic event rate in patients with locally advanced esophageal cancer during perioperative therapy: A pre-planned analysis of the intergroup phase III trial SAKK 75/08

33. Indications and Route of Hysterectomy for Benign Diseases. Guideline of the DGGG, OEGGG and SGGG (S3 Level, AWMF Registry No. 015/070, April 2015)

Catalog

Books, media, physical & digital resources